Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154238 | 0.86 | — | — | |
| SCHEMBL29517969 | 0.76 | CYP2C19 (0.35) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29131768 | 0.75 | ALDH1A1 (0.33) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL1671040 | 0.72 | CYP4F2 (0.35) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL20590813 | 0.72 | CYP2C19 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL320082 | 0.72 | CYP4F2 (0.35) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL12497507 | 0.71 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24173879 | 0.70 | ALDH1A1 (0.49) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL18758225 | 0.70 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL18133767 | 0.70 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022066917-A1 | 3-(6-AMINOPYRIDIN-3-YL)BENZAMIDE DERIVATIVES AS RIPK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | WO | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | CYP4F2 429/4885CYP4A11 261/4885ALDH1A1 3550/4885 |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | CYP4F2 3291/4885CYP4A11 3097/4885ALDH1A1 3194/4885 |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CYP4F2 502/4885CYP4A11 284/4885ALDH1A1 3564/4885 |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | CYP4F2 3841/4885CYP4A11 4214/4885ALDH1A1 4164/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | CYP4F2 2282/4885CYP4A11 670/4885ALDH1A1 1666/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CYP4F2 502/4885CYP4A11 284/4885ALDH1A1 3564/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CYP4F2 502/4885CYP4A11 284/4885ALDH1A1 3564/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | CYP4F2 488/4885CYP4A11 156/4885ALDH1A1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.